Sunpla (Heptaplatin) is a new anti-cancer agent, the third generation of platinum complexes after cisplatin and carboplatin. Sunpla acquired final permission from KFDA (Korea Food & Drug Administration) as the first domestically developed new drug on July 14, 1999 after 9 years of R&D from May 1990.
Clinical studies conducted on Supla demonstrate its ability to treat cancer, especially gastric cancer, the most common type of cancer in Korea. The results of the studies show that its effectiveness in treating cancer matches or exceeds that of existing chemotherapies, with fewer adverse reactions.
|
 |
|
Heptaplatin --------------------------------------- 50mg or 100mg / 1 vial
Treatment of progressive, metastatic or post-operative relapsing gastric cancer combined with 5-fluorouracil.
Intravenously infuse 400mg/m2 of heptaplatin dissolved in 5% glucose solution over 1 hour once daily. Repeat this process every three or four weeks. Dosage and treatment period can be adjusted appropriately according to the type of disease or symptoms. If necessary, perform general hydration therapy before the treatment.
| 1. |
Sunpla (Heptaplatin) is the third generation of platinum complex anti-cancer agents after cisplatin and carboplatin. |
| 2. |
Its effectiveness in treating cancer matches or exceeds that of existing chemotherapies, especially with regard to gastric cancer. |
| 3. |
Supla is a safe anti-cancer agent with mild & low adverse reactions.
Alopecia and neurotoxicity, two of the most serious adverse reactions in chemotherapy were less than degree 2 in Sunpla treatment. In addition, vomiting occurred in only 3.3% of patients, which is much less compared with the 36.5% of existing chemotherapies. |
|
